Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
April 16, 2021

GSK and Vir announce EMA review of VIR-7831 for early treatment of Covid-19

GlaxoSmithKline and Vir Biotechnology have announced the European Medicines Agency (EMA) review of VIR-7831 (GSK4182136) for the early treatment of Covid-19.

Ahead of any formal Marketing Authorisation Application (MAA), the review will assist in EU-wide recommendations for countries that may take evidence-based decisions on the premature use of the  medicine.Credit: Mohamed Hassan/Pixabay.